Skip to main content

Candel Therapeutics Inc

For the period ended Mar 31, 2024. Filed May 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

CADL$8.75+8.8%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

COMMON STOCK · TREASURY STOCK · ADDITIONALPAID-IN · ACCUMULATED · STOCKHOLDERS’
SHARES · AMOUNT · SHARES · AMOUNT · CAPITAL · DEFICIT · EQUITY
Balance, December 31, 202329,213,627$290(122,608)$(448)$149,931$(137,028)$12,745
Options exercised146,9641——225$—226
Stock-based compensation————1,030—1,030
Change in fair value of NC Ohio Trust Warrants————13—13
Sale of common stock, net of issuance costs109,4851185—186
Net loss—————(8,221)(8,221)
Balance, March 31, 202429,470,076$292(122,608)$(448)$151,384$(145,249)$5,979
COMMON STOCK · TREASURY STOCK · ADDITIONALPAID-IN · ACCUMULATED · STOCKHOLDERS’
SHARESAMOUNTSHARESAMOUNTCAPITALDEFICITEQUITY
Balance, December 31, 202229,042,418$290(122,608)$(448)$146,961$(99,089)$47,714
Stock-based compensation————798—798
Change in fair value of NC Ohio Trust Warrants————(65)—(65)
Net loss—————(8,795)(8,795)
Balance, March 31, 202329,042,418$290(122,608)$(448)$147,694$(107,884)$39,652
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.